<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Monomethyl fumarate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Monomethyl fumarate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Monomethyl fumarate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="128096" href="/d/html/128096.html" rel="external">see "Monomethyl fumarate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54703614"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bafiertam</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54359696"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Fumaric Acid Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F54444068"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Multiple sclerosis, relapsing:</b>
<b>Note:</b> In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;display:inline">
<b>Oral:</b> Initial: 95 mg twice daily; after 7 days, increase to the maintenance dose: 190 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54444070"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary.</p></div>
<div class="block doha drugH1Div" id="F54444071"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary.</p></div>
<div class="block dot drugH1Div" id="F54444072"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Side effects with maintenance dose: If the maintenance dose is not tolerated, consider temporary dose reduction to 95 mg twice daily; resume recommended maintenance dose of 190 mg twice daily within 4 weeks. Consider discontinuation in patients who cannot tolerate return to the maintenance dose.</p>
<p style="text-indent:-2em;margin-left:2em;">GI reactions, severe (hemorrhage, obstruction, perforation, ulceration): Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reaction (anaphylaxis or angioedema): Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Lymphocyte count &lt;500/mm<sup>3 </sup>persisting for &gt;6 months: Consider treatment interruption.</p>
<p style="text-indent:-2em;margin-left:2em;">Progressive multifocal leukoencephalopathy: With the first sign/symptom suggestive of progressive multifocal leukoencephalopathy, withhold therapy and perform appropriate diagnostic evaluation.</p>
<p style="text-indent:-2em;margin-left:2em;">Serious infection: Consider withholding treatment until infection resolves.</p></div>
<div class="block doe drugH1Div" id="F54444069"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F54372144"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. All adverse reactions are reported with dimethyl fumarate, the prodrug of monomethyl fumarate.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (18%), diarrhea (14%), nausea (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (60%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (5%) pruritus (8%), skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (5%), vomiting (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Progressive multifocal leukoencephalopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes, increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function, increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Aspergillosis, cytomegalovirus disease, herpes simplex infection, herpes zoster infection (including disseminated, ophthalmicus, meningoencephalitis, and meningomyelitis), listeriosis, opportunistic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea, tuberculosis</p></div>
<div class="block coi drugH1Div" id="F54359687"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema) to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or to any component of the formulation; concomitant use with dimethyl fumarate or diroximel fumarate.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F54444053"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Flushing: May cause mild to moderate flushing (eg, warmth, redness, itching, burning sensation); flushing generally appears soon after initiation, and improves or resolves with subsequent dosing. Administration of aspirin (nonenteric coated ≤325 mg) 30 minutes prior to monomethyl fumarate or a temporary dose reduction may also reduce the incidence and severity of flushing.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI events: Severe GI reactions (eg, hemorrhage, obstruction, perforation, ulceration), including fatalities, occurring within 6 months (majority) of treatment initiation and with or without concomitant aspirin use have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Clinically significant postmarketing cases of hepatic injury have been reported with the prodrug dimethyl fumarate, with an onset ranging from a few days to several months after treatment initiation. Signs/symptoms of hepatic injury, including transaminase elevations &gt;5 times the ULN and total bilirubin elevations &gt;2 times ULN have been observed. Some cases have required hospitalization; however, none of the cases were fatal or resulted in liver failure or transplant. LFT abnormalities resolved upon discontinuation. Drug-induced hepatocellular injury resulting in new-onset transaminase elevations combined with increased bilirubin levels is an important predictor of serious hepatic injury that may lead to acute hepatic failure, liver transplant, or death in some patients. Transaminase elevations (usually &lt;3 times ULN) were observed in clinical trials with dimethyl fumarate; transaminase elevations ≥3 times ULN occurred rarely. Monitor LFTs prior to treatment initiation and during treatment. Discontinue treatment if monomethyl fumarate-induced hepatic injury is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylaxis and angioedema may occur after the first dose or at any time during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Serious cases of herpes zoster (eg, disseminated, ophthalmicus, meningoencephalitis, meningomyelitis) have been reported with the prodrug dimethyl fumarate; may develop any time during treatment. Other serious opportunistic infections have occurred, including viral (eg, <i>Cytomegalovirus</i>, herpes simplex, West Nile), fungal (eg, <i>Aspergillus</i>, <i>Candida</i>), and bacterial (eg, <i>Listeria monocytogenes</i>, <i>Mycobacterium tuberculosis</i>, <i>Nocardia</i>), in patients with and without lymphopenia. Consider temporary interruption of therapy until infection has resolved. In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphopenia: Decreased lymphocyte counts may occur. The risk for lymphopenia is not reduced over time with dimethyl fumarate, the prodrug of monomethyl fumarate. A decline in absolute lymphocyte count (ALC) typically occurs in the first year of treatment and stabilizes. Progressive multifocal leukoencephalopathy (PML) may occur in patients with a lymphocyte count &lt;500/mm<sup>3</sup> for &lt;6 months (Lehmann-Horn 2016). Due to a potential for delayed lymphocyte recovery following treatment interruption or discontinuation, monitor lymphocyte counts until lymphopenia is resolved. The decision to restart monomethyl fumarate should be individualized based on clinical circumstances. Neither monomethyl fumarate nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Cases of PML due to the John Cunningham (JC) virus, including fatality, have been reported with the prodrug dimethyl fumarate. Risk factors for development of PML include HIV, AIDS, cancer history, persistent leukocytopenia, sarcoidosis, and prior immunosuppressant use (Jamilloux 2014; Tan 2010). However, cases have been reported with dimethyl fumarate use in patients who were not immunocompromised and had no prior exposure to immunosuppressive drugs, including natalizumab. Severe, long-standing lymphopenia was identified as a primary risk for PML, and the majority of PML cases occurred in patients with lymphocyte counts &lt;800/mm<sup>3</sup> persisting for &gt;6 months (although the exact role of lymphopenia in PML is unknown). At the first sign or symptom suggestive of PML, withhold therapy immediately and perform a diagnostic evaluation; symptoms progress over days to weeks and may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and mental status changes. Cases of PML have been diagnosed based on MRI findings and the detection of JC virus DNA in the cerebrospinal fluid without specific PML signs/symptoms. Monitoring with brain MRI for signs that may be consistent with PML may be beneficial and allow for an early diagnosis of PML (EMA 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued monomethyl fumarate; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p></div>
<div class="block foc drugH1Div" id="F54703615"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bafiertam: 95 mg [contains peg-40 hydrog castor oil(cremophor rh40)]</p></div>
<div class="block geq drugH1Div" id="F54703613"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54783492"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Bafiertam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">95 mg (per each): $66.39</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F54444073"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Swallow capsules whole and intact; do not crush, chew, or mix the contents with food. Administer with or without food. Administration of non–enteric-coated aspirin up to a dose of 325 mg 30 minutes prior to monomethyl fumarate may reduce the incidence of flushing.</p></div>
<div class="block use drugH1Div" id="F54359686"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Multiple sclerosis, relapsing:</b> Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.</p></div>
<div class="block mst drugH1Div" id="F54444048"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Monomethyl fumarate may be confused with dimethyl fumarate.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54402609"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54402606"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Fumarate: Monomethyl Fumarate may enhance the adverse/toxic effect of Dimethyl Fumarate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diroximel Fumarate: Monomethyl Fumarate may enhance the adverse/toxic effect of Diroximel Fumarate. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54444051"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy except in females at high risk of MS activity (AAN [Rae-Grant 2018]). Consider use of agents other than monomethylfumarate for females at high risk of disease reactivation who are planning a pregnancy. Delaying pregnancy is recommended for females with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F54444050"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/ EAN [Montalban 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to monomethyl fumarate during pregnancy are encouraged to contact the manufacturer at 866-663-9564.</p></div>
<div class="block brc drugH1Div" id="F54444052"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if monomethyl fumarate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Based on the low molecular weight and low protein binding, transfer of monomethyl fumarate into breast milk is expected. Until additional information is available, other sources do not recommend breastfeeding during therapy (Almas 2016; Dobson 2019).</p></div>
<div class="block mop drugH1Div" id="F54444075"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC including lymphocyte counts (prior to initiation of therapy, 6 months after initiation, then every 6 to 12 months thereafter as clinically necessary); LFTs including transaminases, alkaline phosphatase, and total bilirubin (prior to treatment initiation and during treatment as clinically indicated); signs of infection in patients with lower lymphocyte counts at baseline and mild to moderate lymphopenia (Baharnoori 2018); MRI (baseline and as clinically indicated to monitor for early signs of progressive multifocal leukoencephalopathy); latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline); signs and symptoms of severe GI reactions.</p></div>
<div class="block pha drugH1Div" id="F54444059"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Monomethyl fumarate (MMF) and its prodrug, dimethyl fumarate, have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which is involved in cellular response to oxidative stress. The mechanism by which monomethyl fumarate exerts a therapeutic effect in multiple sclerosis is unknown, although it is believed to result from its anti-inflammatory and cytoprotective properties via activation of the Nrf2 pathway (Fox 2012; Gold 2012). MMF has also been identified as a nicotinic acid receptor agonist in vitro.</p></div>
<div class="block phk drugH1Div" id="F54444060"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">Absorption: High-fat, high-calorie meals prolong absorption and decrease C<sub>max </sub>by 20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d ­</sub>(prodrug dimethyl fumarate): 53 to 73 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Prodrug dimethyl fumarate: 27% to 45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Through the tricarboxylic acid cycle, with no involvement of the CYP-450 system.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~0.5 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4.03 hours; after high-fat meal: 11 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: From studies with dimethyl fumarate: Exhalation of CO<sub>2</sub>: ~60% of dimethyl fumarate; urine (16% of dimethyl fumarate; trace amounts as unchanged monomethyl fumarate); feces (1% of dimethyl fumarate).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216148"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bafiertam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26966579">
<a name="26966579"></a>Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. <i>Mult Scler Int</i>. 2016;2016:6527458. doi:10.1155/2016/6527458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/26966579/pubmed" id="26966579" target="_blank">26966579</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bafiertam (monomethyl fumarate) [prescribing information]. High Point, NC: Banner Life Sciences LLC; May 2021.</div>
</li>
<li>
<div class="reference">
                  Bafiertam (monomethyl fumarate) [prescribing information]. High Point, NC: Banner Life Sciences LLC; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29304497">
<a name="29304497"></a>Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. <i>Mult Scler Relat Disord</i>. 2018;20:51‐57. doi:10.1016/j.msard.2017.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/29304497/pubmed" id="29304497" target="_blank">29304497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30612100">
<a name="30612100"></a>Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. <i>Pract Neurol</i>. 2019;19(2):106‐114. doi:10.1136/practneurol-2018-002060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/30612100/pubmed" id="30612100" target="_blank">30612100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.1">
<a name="EMA.1"></a>European Medicines Agency (EMA). Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. https://www.ema.europa.eu/ema. Published October 23, 2015. Accessed May 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22992072">
<a name="22992072"></a>Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [published correction appears in <i>N E</i>
<i>ngl J Med</i>. 2012;367(17):1673]. <i>N Engl J Med</i>. 2012;367(12):1087‐1097. doi:10.1056/NEJMoa1206328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/22992072/pubmed" id="22992072" target="_blank">22992072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22992073">
<a name="22992073"></a>Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis [published correction appears in<i> N </i>
<i>Engl J Med</i>. 2012;367(24):2362]. <i>N Engl J Med</i>. 2012;367(12):1098‐1107. doi:10.1056/NEJMoa1114287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/22992073/pubmed" id="22992073" target="_blank">22992073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24610328">
<a name="24610328"></a>Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. <i>Neurology</i>. 2014;82(15):1307‐1313. doi:10.1212/WNL.0000000000000318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/24610328/pubmed" id="24610328" target="_blank">24610328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27343070">
<a name="27343070"></a>Lehmann-Horn K, Penkert H, Grein P, et al. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? <i>Neurology</i>. 2016;87(4):440‐441. doi:10.1212/WNL.0000000000002900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/27343070/pubmed" id="27343070" target="_blank">27343070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215‐237. doi:10.1111/ene.13536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686116">
<a name="29686116"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology [published correction appears in <i>Neurology</i>. 2019;92(2):112]. <i>Neurology</i>. 2018;90(17):777‐788. doi:10.1212/WNL.0000000000005347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/29686116/pubmed" id="29686116" target="_blank">29686116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20298966">
<a name="20298966"></a>Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. <i>Lancet Neurol</i>. 2010;9(4):425‐437. doi:10.1016/S1474-4422(10)70040-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/monomethyl-fumarate-drug-information/abstract-text/20298966/pubmed" id="20298966" target="_blank">20298966</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 128079 Version 46.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
